The ability of a viral vector to safely deliver and stably integrate large transgene units (transgenons), which not only include one or several therapeutic genes, but also requisite native transcriptional regulatory elements, would be of significant benefit for diseases presently refractory to available technologies. The herpes simplex virus type-1 (HSV-1) amplicon vector has the largest known payload capacity of approximately 130 kb, but its episomal maintenance within the transduced cell nucleus and induction of host cell silencing mechanisms limits the duration of the delivered therapeutic gene(s). Our laboratory developed an integration-competent version of the HSV-1 amplicon by adaptation of the Sleeping Beauty (SB) transposon system, which significantly extends transgene expression in vivo. The maximum size limit of the amplicon-vectored transposable element remains unknown, but previously published plasmidcentric studies have established that DNA segments longer than 6-kb are inefficiently transposed. Here, we compared the transposition efficiency of SB transposase in the context of both the HSV amplicon vector as well as the HSV amplicon plasmid harboring 7 and 12-kb transposable reporter transgene units. Our results indicate that the transposition efficiency of the 12-kb transposable unit via SB transposase was significantly reduced as compared with the 7-kb transposable unit when the plasmid version of the HSV amplicon was used. However, the packaged HSV amplicon vector form provided a more amenable platform from which the 12-kb transposable unit was mobilized at efficiency similar to that of the 7-kb transposable unit via the SB transposase. Overall, our results indicate that SB is competent in stably integrating transgenon units of at least 12 kb in size within the human genome upon delivery of the platform via HSV amplicons.
Introduction
Development of novel viral vector-based therapeutics for currently clinically intractable human diseases may require regulated long-term expression of the therapeutic gene(s) to provide long-lasting benefit. Current strategies have focused on the use of adeno-associated virus (AAV) vectors and lentiviral vectors that intrinsically integrate their genetic payload within the host-cell genome, thus facilitating stable genome maintenance and sustained expression of the therapeutic gene. Based on their inherent biological characteristics, however, AAV and lentiviral viral vectors are limited to genetic segment lengths of 4 and 9 kb, respectively.
1,2 These size restrictions unfortunately preclude the development of gene therapeutics for disorders that require efficient delivery of genes longer than 9 kb. Hence, there is an apparent need in the field to develop and experimentally validate new vector platforms that may significantly raise the size barrier, and at the same time, provide stable therapeutic gene expression in vivo.
The herpes simplex virus type-1 (HSV-1) amplicon holds a significant advantage over all other currently available viral vectors due to its B130-kb payload capacity, thus enabling delivery of multiple transgene units together with transcription-regulatory elements for stringent control of gene expression. 3 However, long-term expression of transgenes delivered via the HSV amplicon has been challenging due to the episomal existence of the HSV genome within the transduced-cell nucleus, its propensity to be segregated mitotically and its susceptibility to hostcell-mediated silencing of the amplicon-encoded genetic units. 4 Thus, development of integration-competent versions of the HSV amplicon have been undertaken via use of viral and non-viral elements that facilitate stable integration of the delivered transgene within the transduced-cell genome. One such vector is the HSV/AAV hybrid amplicon, which includes the Rep-coding sequence and the inverted terminal repeats of the AAV genome built into the HSV amplicon backbone. This hybrid amplicon system has shown to prolong transgene expression in cell culture and also facilitate site-specific integration of the inverted terminal repeat-flanked transgene unit into the AAVS1 locus in hChr19. 5, 6 As an alternative strategy, our laboratory previously engineered a bipartite HSV amplicon vector platform using the nonviral elements of the Sleeping Beauty (SB) transposon system, 7 which enabled efficient integration of a transposable transgene unit, termed transgenon, within the To generate 7-and 12-kb transposable segments, the CMV-eGFP/Neo-SV40 polyA (2.5 kb) transcription unit was excised from the pBSFBR-CMV-eGFP/Neo construct using NotI (New England Biolabs, Ipswich, MA, USA) and cloned into the corresponding NotI site in a previously engineered PmeI site-containing pBSIIKS(+) shuttle vector to generate pBSIIKS/P_CMV-eGFP/Neo. Subsequently, a 4.5-kb non-coding spacer DNA fragment was obtained by digestion of pDelta28E4 (kindly provided by Dr Brendan Lee) with HindIII, and was cloned into the corresponding HindIII site 5 0 to the CMV-eGFP/Neo transcription unit to generate pBSIIKS_CMV-eGFP/Neo_4.5 kb. Thereafter, the CMV-eGFP/Neo (2.5 kb) transcription unit plus the 4.5-kb spacer DNA fragment were excised using PmeI. This 7-kb segment was cloned into a blunted NotI site in the pHSVTmcs amplicon to generate the pHSVT-CMV-eGFP/Neo_7-kb amplicon plasmid. To extend the size of the transposable segment to 12 kb, a 5-kb non-coding spacer fragment, which was also obtained from the pDelta28E4 plasmid via digestion with FspI, was cloned into a blunted ClaI site located upstream of the 4.5-kb spacer fragment within pHSVT-CMV-eGFP/Neo_7 kb to generate pHSVT-CMV-eGFP/Neo_12 kb. Both constructs were verified by DNA sequence analysis and subsequently packaged into helpervirus-free HSV amplicon particles and viral titers were determined as described previously. 15 (c, d) To verify eGFP expression from both pHSVT-CMV-eGFP/Neo_7-kb and pHSVT-CMV-eGFP/Neo_12-kb amplicon plasmids, separate cultures of 5 Â 10 4 HeLa cells were transfected with each construct using FuGENE6 transfection reagent (Roche Diagnostics Corporation, Indianapolis, IN, USA) and visualized by fluorescence microscopy 48 h following transfection. (e, f) Similarly, eGFP expression derived from packaged HSV amplicon particles was confirmed by transducing HeLa-cell monolayers using HSVT-CMV-eGFP/Neo_7-kb and HSVT-CMV-eGFP/Neo_12-kb virus at a multiplicity of infection of 0.1 for 1 h at 37 1C. After the 1-h incubation period, virus-containing media was removed and the cells were rinsed once with media and subsequently replenished with fresh media. eGFP expression was observed by fluorescence microscopy 48 h following transduction. CMV, cytomegalovirus; eGFP, enhanced green fluorescent protein; HSV, herpes simplex virus; IR, inverted repeat; Neo, neomycin phosphotransferase; SB, Sleeping Beauty. 
(305) (316) Figure 2 Assessing the transposition efficiency of the SB transposase in the context of HSV amplicon plasmids harboring differently sized transposable units. HeLa cells (1 Â 10 5 cells per well) were co-transfected with 165 ng of the plasmid versions of the HSV amplicon vectors expressing either the 'wild-type' SB transposase (pHSV-SB10) or the hyperactive HSB5 transposase (pHSV-HSB5), together with either 116 ng of the pHSVT-CMV-eGFP/Neo_7-kb amplicon or 165 ng of the pHSVT-CMV-eGFP/Neo_12-kb amplicon using the FuGENE6 transfection reagent (Roche). The pHSVPrPUC empty vector plasmid was transfected with each of the differently sized eGFP/Neo transposon-harbored amplicons to determine the number of G418-resistant colonies that had arisen due to random integration events in the absence of the SB transposase. To ensure equal amounts of DNA were transfected under each condition, the pHSVPrPUC empty vector was used as 'filler' DNA. (a, b) eGFP expression was assessed 48 h following transfection by fluorescence microscopy to determine the transfection efficiency of the pHSVT-CMV-eGFP/Neo_7-kb and the pHSVT-CMV-eGFP/Neo_12-kb amplicon plasmids in the presence of the SB-expressing amplicon plasmid. (c) Thereafter, the cells were trypsinized and seeded at a 1:3 dilution on 100-mm dishes and placed under 600 mg ml À1 G418 selection for a period of 2 weeks. Subsequently, cells were fixed with 4% paraformaldehyde and stained with 2% methylene blue, washed extensively with dH 2 O and blue colonies were enumerated. (d) The transposition efficiency of SB10 and HSB5 in the presence of either the 7-or 12-kb transposons is represented as a fold change in the number of G418-resistant colonies compared with when the SB transposase was absent. The average number of G418-resistant colonies (n ¼ 3) corresponding to each group is indicated in parentheses above each bar in the histogram. Error bars represent standard error. Statistical analysis was performed using the Student's t-test and P-values are indicated. CMV, cytomegalovirus; eGFP, enhanced green fluorescent protein; HSV, herpes simplex virus; Neo, neomycin phosphotransferase; SB, Sleeping Beauty.
HSV/SB-mediated integration of large transgenons S de Silva et al genome of the transduced target cell and extended the expression of a reporter transgene in vivo. 8, 9 The Rous sarcoma virus 5 0 inverted terminal repeat promoterregulated b-galactosidase/neomycin phosphotransferase (Neo) fusion reporter transgene unit used in this initial study was 4.6 kb in size and when flanked by the inverted repeat elements (IR/DR) of SB, was efficiently transposed via the 'wild-type' SB10 transposase expressed through a co-delivered HSV amplicon. However, the transposable size limit of this platform is yet to be determined.
Previous reports have demonstrated that plasmidbased delivery of SB IR/DR-flanked reporter transgenes are efficiently transposed up to size of 6 kb, with an exponential decrease in SB-mediated transposition efficiency as the size of the transposon is increased to sizes greater than 6 kb. [10] [11] [12] The generation of the modified 'sandwich' transposon system by Zayed et al. 13 has been shown to increase the transposable payload limit to B10 kb from plasmid-based vectors. Additionally, the sequences that flank the transposon within the donor plasmid, as well as the efficiency by which the donor construct is delivered into the target-cell nucleus, are factors, which may significantly affect the transposition efficiency of SB. 10 Given the large packaging capacity of conventional HSV-derived vectors, it is possible that the HSV/SB bipartite platform could provide a means to integrate transgene units that exceed the 9-kb limit afforded by lentiviral vectors. Here, we tested whether a 12-kb transposable unit could be efficiently mobilized by either 'wild-type' SB transposase (SB10) or a hyperactive version of the SB transposase (termed HSB5 14 ) from the context of an HSV amplicon vector into a human-cell genome. Successful mobilization and integration would demonstrate that an integration-competent platform exists that can integrate transgenons up to 12 kb, thereby expanding the number of potential disease targets amenable to HSV amplicon-based therapeutic modalities.
Results and discussion
The HSV/SB bipartite amplicon vector platform consists of an HSV-SB amplicon vector, which expresses in trans the SB transposase gene under the transcriptional regulation of the HSV IE 4/5 promoter and an integrationcompetent reporter amplicon vector (termed HSVT-CMV-eGFP/Neo) that harbors the SB IR/DR elements, which in turn flank an enhanced green-fluorescent protein (eGFP) fused to a Neo gene (eGFP/Neo) under the transcriptional regulation of the cytomegalovirus (CMV) promoter (Figure 1a ). To test whether the current HSV/SB amplicon vector platform could deliver and stably integrate large trangene units within the humancell genome, we constructed two differently sized transposable reporter units (7 and 12 kb) within the HSVT-CMV-eGFP/Neo vector by incorporating noncoding, spacer DNA fragments 5 0 of the CMV-eGFP/ Neo transcription unit to generate the pHSVT-CMVeGFP/Neo_7-kb and pHSVT-CMV-eGFP/Neo_12-kb amplicon plasmids (Figure 1b) . eGFP expression from these HSVT amplicon plasmids was confirmed in HeLa cells 48 h following transfection by fluorescence microscopy (Figures 1c and d) . Subsequently, helper virus-free packaging technology was used to produce the HSVT-CMV-eGFP/Neo_7-kb and HSVT-CMV-eGFP/Neo_ 12-kb amplicon stocks as described previously, 15 and eGFP expression was confirmed in HeLa cells by fluorescence microscopy 48 h following transduction (Figures 1e and f) .
To test the transposition efficiency of the 'wild-type' transposase (SB10) as well as a hyperactive version of the SB transposase (HSB5 14 ) in the context of the HSV amplicon plasmids harboring the 7-and 12-kb transposable units, we performed a colony-forming assay using HeLa cells (Figure 2 ). An equivalent amount of the SB transposase-expressing HSV amplicon plasmid (pHSV-SB10 or pHSV-HSB5) was co-transfected with either the pHSVT-CMV-eGFP/Neo_7-kb or pHSVT-CMV-eGFP/Neo_12-kb amplicon plasmid in HeLa cells. As depicted in representative images in Figures 2a and b , a comparable number of cells were transfected with the differently sized transposable reporter constructs as detected by fluorescence microscopy 48 h following transfection. Two days following transfection, the cells were placed under G418 selection for a period of 2 weeks, at which point the G418-resistant colonies were fixed with 4% paraformaldehyde, stained with methylene blue and enumerated to determine the transposition level ( Figure 2c ). The pHSVPrPUC amplicon plasmid served as an empty vector control to assess the number of G418-resistant colonies arising from random integration events of the pHSVT-CMV-eGFP/Neo_7-kb and pHSVT-CMV-eGFP/Neo_12-kb amplicon plasmids. The efficiency of each SB transposase to mobilize the IR/DRflanked units was represented as fold change relative to the pHSVPrPUC empty vector control, where SB transposase was absent. As shown in Figure 2d the SB10 transposase exhibited a 1.43-fold increase in the transposition efficiency of the 7-kb transposable unit as compared with that of the pHSVPrPUC empty vector control. Furthermore, as the size of the transposable unit was increased to 12 kb, the transposition efficiency of SB10 decreased by 10% as shown in Figure 2d . The hyperactive HSB5 transposase, which has been predicted to form a more stable synaptic complex, 14 showed a higher fold change in transposition efficiency with the 7-kb transposable unit as compared with that using the SB10 transposase (Figure 2d) . However, the transposition efficiency of HSB5 pertaining to the 12-kb transposable unit was diminished to levels similar to that with the SB10 transposase. These results are consistent with previous studies that assessed the transposable cargo capacity of the 'wild-type' SB transposase, where a significant decrease in the transposition efficiency was observed as the size of the transposable segment exceeded 6 kb. [10] [11] [12] Additionally, our results suggest that use of hyperactive mutants of the SB transposase may be beneficial in enhancing the transposition efficiency of transgene units p7 kb, but does not appear to significantly impact the efficiencies of transposing larger transgene segments from the context of plasmid-based vectors. The observed diminution in transposing large DNA segments (46 kb) via the SB transposase from the context of a plasmid-based vector could be due to several factors: (1) inefficient transport/delivery of large DNA molecules from the plasma membrane into the host-cell nucleus; (2) the inability to form a functional synaptic complex due to the large intervening DNA segment between the IR/DR elements 10, 12 and/or 3 the length and sequence features of the DNA flanking the IR/DR HSV/SB-mediated integration of large transgenons S de Silva et al elements, which comprise the plasmid-vector backbone, may unduly influence the transposition process. 10, 16 Considering the limitations associated with SBmediated transposition of large transgene units from plasmids, we assessed whether a transposon-harbored HSV amplicon particle might provide a more amenable platform from which large transgene units could be efficiently mobilized into the host-cell genome. To this end, we individually co-transduced either packaged HSV-SB10 or HSV-HSB5 amplicon with the HSVT-CMV-eGFP/Neo_7-kb and HSVT-CMV-eGFP/Neo_ 12-kb amplicons and performed a colony formation assay as described above. As depicted in representative images in Figures 3a and b were transduced with the differently sized transposable reporter amplicons in the presence of the SB-expressing amplicons 48 h following transduction. After 2 weeks of G418 selection, the colonies were analyzed by fluorescence microscopy to confirm eGFP expression (Figures 3c  and d ) and subsequently stained with methylene blue (Figure 3e ), and colonies were enumerated to assess the transposition efficiency of the 7 and 12-kb transgenon units in the presence of the 'wild-type' and hyperactive SB transposases (Figure 3f ). Upon enumeration of the G418-resistant colonies, we observed a 5.18-fold increase in the transposition efficiency when the HSVT-CMVeGFP/Neo_7-kb amplicon was co-delivered with the HSV-SB10 amplicon compared to the empty vector control (HSVPrPUC) (Figure 3f) . Furthermore, the HSB5 transposase expressed via the HSV amplicon increased the transposition efficiency of the 7-kb transposable unit by 33% over the 'wild-type' SB10 transposase. When the HSVT-CMV-eGFP/Neo_12-kb amplicon was co-transduced with either the HSV-SB10 or HSV-HSB5 amplicons, we observed a 4.28-and 4.88-fold increase in the transposition efficiency, respectively, as compared with the increase when the HSVPrPUC control amplicon was present. Although a decrease in the transposition efficiency was observed with SB10 and HSB5 transposase when the size of the transposon was increased from 7 to 12 kb within the HSV amplicon, it was significantly higher than plasmid-based transposition of identically sized transposable units.
To determine the fold increase in transposition efficiency of a 12-kb transgenon from the HSV amplicon as compared with the plasmid version of the amplicon, we calculated the transposition efficiency per 12-kb unit delivered via each modality. We initially calculated the numbers of 12-kb transgenon copies used during monolayer transduction by multiplying the numbers of transduced viral particles by the value obtained by dividing 150 kb (wild-type HSV genome size) by the total size of the transgenon-harbored amplicon in kilobases. This number was subsequently divided into the number of G418-resistant colonies resulting from SB-mediated transposition events (total number of G418-resistant colonies minus the number of background G418-resistant colonies resulting from SB-independent integration). The frequency of transposition per 12-kb transposable unit was determined to be 4.94 Â 10
À4
. Similarly, the frequency of transposition from the plasmid version of the HSV amplicon was calculated using the numbers of 12-kb transgenon units contained within 165 ng of transfected pHSVT-CMV-eGFP/Neo_12-kb plasmid DNA and the numbers of G418-resistant colonies resulting from SB transposition. The frequency of transposition from the amplicon plasmid was 3.01 Â 10 À11 per 12-kb transposable unit. Hence, our results indicate that the frequency of SB-mediated transposition of the 12-kb transgenon from the HSV amplicon was approximately 1.7 Â 10 7 -fold higher than that from plasmid-based transposition.
To confirm SB-mediated integration of the eGFP/Neomarked 7 and 12-kb transposable units in the HeLa-cell genome, Southern blot analysis was performed using an eGFP/Neo-specific radiolabeled DNA probe (917 bp) on Figure 3 The SB transposase is competent in efficiently mobilizing a 12-kb transposable unit from the context of an HSV amplicon vector. HeLa cells (1 Â 10 5 cells per well) were co-transduced with HSV amplicon vectors expressing either the 'wild-type' SB transposase (HSV-SB10) or the hyperactive HSB5 transposase (HSV-HSB5), together with either the HSVT-CMV-eGFP/Neo_7-kb amplicon or the HSVT-CMV-eGFP/Neo_12-kb amplicon at a multiplicity of infection of 1.0. Upon incubation for 1 h at 37 1C, the virus-containing medium was removed and cells were washed once and replenished with fresh media. (a, b) eGFP expression was assessed 48 h following transduction by fluorescence microscopy to determine the transduction efficiency of the HSVT-CMV-eGFP/Neo_7-kb and HSVT-CMV-eGFP/Neo_12-kb amplicons in the presence of the co-delivered SB-expressing amplicon vector. Subsequently, the cells were trypsinized and seeded at a 1:3 dilution on 100-mm dishes and placed under 600 mg ml À1 G418 selection for a period of 2 weeks. (c, d) After 2 weeks, G418-resistant colonies were fixed with 4% paraformaldehyde and analyzed by fluorescence microscopy for eGFP expression. Representative images of G418-resistant colonies 2 weeks post-transduction of HSVT-CMV-eGFP/Neo_12 kb either with HSV-SB10 or HSV-HSB5 are shown. (e) Upon confirmation of eGFP expression, the G418-resistant colonies were stained with 2% methylene blue, washed extensively with dH 2 O and blue colonies were enumerated. (f) The transposition efficiency of SB10 and HSB5 in the presence of either the 7-or 12-kb transposon-harboring HSVT amplicons is represented as a fold change in the number of G418-resistant colonies as compared with when the SB transposase was absent (HSVPrPUC control amplicon). The average number of G418-resistant colonies (n ¼ 3) corresponding to each group is indicated in parentheses above each bar in the histogram. Error bars represent standard error. Statistical analysis was performed using Student's t-test and P-values are indicated. (g) Schematic representations of integrated configurations of the T-CMV-eGFP-Neo_7-kb and T-CMV-eGFP-Neo_12-kb transgenons and their concatemeric amplicon genome counterparts. The relative locations of the signature EcoRV restriction enzyme recognition sites and the location of a DNA probe used in subsequent Southern blot analyses are depicted. (h) Similarly, G418-resistant colonies that were co-transduced with either HSV-SB10 or HSV-HSB5 and HSVT-CMV-eGFP/Neo_7 kb or HSVT-CMV-eGFP/Neo_12 kb were trypsinized and expanded in 60-mm dishes for the purpose of isolating genomic DNA for Southern blot analysis to determine chromosomal integration of the 7-and 12-kb transposons. Once confluent, these transduced HeLa-cell monolayers were lysed using lysis buffer (10 mM Tris-Cl, 100 mM NaCl, 25 mM EDTA and 0.5% SDS) and genomic DNA was isolated using phenol:chloroform extraction followed by ethanol precipitation. Ten micrograms of genomic DNA was digested with EcoRV, which cuts once within the 7-kb transposable unit 5 0 of the CMV-eGFP-Neo transcription unit and twice within the 12-kb transposable unit. The digested genomic DNA was electrophoresed on 0.8% TAE agarose gel and transferred to a nylon membrane, UV cross-linked and probed with a a-32 P-dCTP-radiolabeled eGFP/Neo probe (917 bp), which was obtained by excising the eGFP-Neo fragment from the pBSFBR-CMV-eGFP-Neo vector using Pst1 and BamHI. The 1-kb plus DNA ladder (Invitrogen, Carlsbad, CA, USA) was radiolabeled according to the manufacturer's recommendations (lane 1); 'c' indicates HSV amplicon units generated by EcoRV digestion of the episomal HSV amplicon concatemer or integrated concatemeric transgenon units, while 'arrows' indicate the predicted SB-mediated integration events within the HeLa-cell genome and '*' demarcates clones later analyzed by integration-site mapping. (i) To determine the integration sites of the 7-kb and 12-kb transposable units within the HeLa-cell genome, linker-mediated PCR (LM-PCR) analysis was conducted using the GenomeWalker Universal Kit (Clontech, Mountain View, CA, USA) according to the manufacturer's recommendations. Chromosomal sequences flanking the right IR/DR junction of the 7-and 12-kb transposable units were PCR-amplified from genomic DNA samples that were analyzed by Southern blotting using a nested primer set as described by Largaespada et al., 25 and cloned into the TOPO-TA vector (Invitrogen) for subsequent sequence analysis. CMV, cytomegalovirus; eGFP, enhanced green fluorescent protein; HSV, herpes simplex virus; IR, inverted repeat; Neo, neomycin phosphotransferase; SB, Sleeping Beauty.
HSV/SB-mediated integration of large transgenons S de Silva et al genomic DNA isolated from G418-resistant colonies arising from co-transduction of the SB transposaseexpressing HSV amplicons with either HSVT-CMVeGFP-Neo_7-kb and HSVT-CMV-eGFP-Neo_12-kb amplicons. The EcoRV-generated B11.5 and B10-kb eGFP/ Neo-positive radiolabeled bands that arise, respectively, in the HSVT-CMV-eGFP-Neo_7-kb and HSVT-CMVeGFP-Neo_12-kb amplicon samples result from detection of either the retained episomal amplicon genomes within the transduced cell or integrated concatemeric copies of the transgenon resulting from the usage of non-consecutive IR/DR sites by SB transposase during transposition (see schematic in Figure 3g ). Our results indicate that the 'wild-type' SB10 transposase and the hyperactive HSB5 transposase mediated an average of 1-2 integration events per G418-resistant colony for each of the 7 and 12-kb transposable units (Figure 3h ). The additional eGFP-Neo-positive bands in each lane result from EcoRV restriction-digest patterns consistent with integration of either the 7 or 12-kb transposable units within the HeLa-cell genome. Furthermore, in certain clones, such as HSV-HSB5+HSVT-CMV-eGFP/Neo_ 7-kb clone no. 6 and HSV-HSB5+HSVT-CMV-eGFP/ Neo_12-kb clone no. 2, it is evident that the hyperactive HSB5 transposase integrated single transgenon units from the HSV amplicon. Linker-mediated PCR analysis was also performed on a subset of genomic DNA samples from G418-resistant colonies to determine the flanking genomic sequences of the integrated 7 and 12-kb transposable units within the HeLa-cell genome (Figure 3i ). The presence of the cttcaaCTGTA signature sequence of the right IR/DR junction flanked by chromosomal DNA sequences indicated that SB transposase followed its characteristic 'cut-and-paste' mechanism of transposition with the integration of large transposable units into chromosomal TA-dinucleotide sites, which are duplicated following SB-mediated integration. Overall, these results indicate that delivery of large transgenon units via HSV amplicon particles provides a more amenable substrate for the SB transposase for integration into the human genome than plasmid vectors harboring the same transposable segments delivered via currently available lipid-based DNA delivery methods.
We hypothesize that the increased ability of the HSV/ SB amplicon vector platform to facilitate integration of large transgenon units within the human genome could occur for several reasons. First, the enclosure of the transposon-encoded HSV amplicon genome within the nucleocapsid leads to efficient delivery of its genetic cargo into the transduced-cell nucleus. Second, certain viral tegument proteins, as well as packaging cell line-derived proteins co-packaged within the HSV virion, 15 may enhance the transposition process of large transposable units from the HSV amplicon. It has been reported previously that SB-mediated transposition involves host-cell factors such as high-mobility-group DNA-binding protein (HMGB1) 13, 17 and DNA-PKcs/Ku, which are members of the non-homologous DNA-repair pathway, 18, 19 and transcription factors that regulate the cell cycle, such as Miz-1. 20 Zayed et al. 17 demonstrated that HMGB1 interacted with SB transposase and increased its binding affinity to the inner DR element, possibly facilitating the formation of the synaptic complex for efficient transposition. Furthermore, transient overexpression of HMGB1 resulted in an enhancement in the transposition efficiency of SB in mouse embryonic fibroblasts 17 and HeLa cells. 13 Thus, the presence of packaging-cell-line-derived HMGB1 protein in HSV viral stocks could inadvertently set up an optimized platform for mobilizing large transgenons from the HSV amplicon vector. Third, the circularization of the HSV amplicon vector genome upon entry into the transduced-cell nucleus could facilitate efficient synaptic complex formation between the IR/DR elements that flank these large transgene units and the SB transposase. Finally, SB-mediated transposition has been shown to be more efficient from a chromosomal context harboring a multi-copy transposon donor substrate in comparison with a single-copy donor locus. 21, 22 Thus, the head-to-tail configuration of the concatemeric, transposon-encoded HSV genome may provide a better substrate for the SB transposase to catalyze its excision and integration events. However, further investigations are required to confirm the characteristics of the HSV amplicon-vector genome that facilitate efficient transposition of large transposable units via the SB transposon system.
The integration-competent HSV/SB amplicon vector platform is a versatile gene delivery modality for genetic diseases that require long-term expression of the therapeutic gene(s) within the affected target cell population. For the first time we have demonstrated that the this gene delivery platform is capable of effectively mobilizing transgene segments up to at least 12 kb into the human genome, thereby exceeding the current integration capacity of adeno-associated viral vectors and lentiviral vectors. This allows delivery of multiple therapeutic genes, as well as native transcriptional regulatory elements, to increase the efficacy and cell specificity of treatment strategies for multi-factorial genetic diseases. We also hypothesize that further optimization of the HSV/SB amplicon vector platform with the use of more hyperactive versions of the SB transposase (such as the SB100X 22 ) coupled with incorporation of more optimized IR/DR elements (such as the T2 23 and 'sandwich-based' IR/DR elements 13 ) into the HSV amplicon vector, may further extend the upper bounds of SB-mediated transposable capacity. Although we have demonstrated that the current bipartite HSV/SB amplicon vector platform mobilizes large transgenon segments into the human genome, it still manifests a random integration profile characteristic of SB, with the attendant potential risk of insertional mutagenesis. 8, 24 Thus, it would be advantageous to target the integration of transgenons to a 'safe' chromosomal location within the human genome, which would increase the safety profile of the HSV/SB amplicon vector platform and expedite its translation to clinical testing.
